List of Pifeltro drug patents
Pifeltro is owned by Msd Merck Co.
Pifeltro contains Doravirine.
Pifeltro has a total of 1 drug patent out of which 0 drug patents have expired.
Pifeltro was authorised for market use on 30 August, 2018.
Pifeltro is available in tablet;oral dosage forms.
Pifeltro can be used as for use in combination with other antiretroviral agents for the treatment of hiv-1 as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to doravirine; for use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; for use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen if virologically suppressed.
Drug patent challenges can be filed against Pifeltro from August, 2022.
The generics of Pifeltro are possible to be released after 07 October, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Oct, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 30, 2023 |
| New Indication (I) | Sep 19, 2022 |
| New Patient Population (NPP) | Jan 27, 2025 |
Drugs and Companies using DORAVIRINE ingredient
NCE-1 date: August, 2022
Market Authorisation Date: 30 August, 2018
Treatment: For use in combination with other antiretroviral agents for the treatment of hiv-1 as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to doravirine; For use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen if virologically suppressed
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic